Cardioprotective Properties of Vegan Burger (VeganBurger)
Primary Purpose
Cardiometabolic Health
Status
Recruiting
Phase
Not Applicable
Locations
Greece
Study Type
Interventional
Intervention
Conventional burger
Vegan burger
Sponsored by

About this trial
This is an interventional treatment trial for Cardiometabolic Health focused on measuring read meat, meat analogues, burger, vegan burger, dietary intervention, plant proteins, inflammation, oxidative stress, thrombosis, cardioprotection
Eligibility Criteria
Inclusion Criteria:
- Age 30-60 years old
- Body mass index ≥25 kg/m2
- Habitual red meat consumption ≥3 portions/week (1 portion: 120 g cooked meat)
Exclusion Criteria:
- Presence of chronic diseases, such as diabetes mellitus, active cancer, cardiovascular, liver kidney, respiratory, gastrointestinal, chronic inflammatory and psychiatric diseases
- Reception of immunosuppressant, anti-inflammatory or cortisol medication,
- Intake of protein, amino acid, fatty acid, dietary fiber, probiotic and prebiotic supplements
- Habitual excessive alcohol consumption, i.e., >210 g and >140 g of ethanol per week for men and women, respectively
- Currently being on a restrictive diet (e.g., weight loss or vegetarian diet) or any significant recent change (within 6 months) in lifestyle habits
- Pregnancy and breastfeeding for women
Sites / Locations
- Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Conventional burger group
Vegan burger group
Arm Description
This arm will consume 2 portions (each 120 g cooked) of conventional burger per week for a 4-week period.
This arm will consume 2 portions (each 120 g cooked) of vegan burger per week for a 4-week period.
Outcomes
Primary Outcome Measures
Change from baseline in homeostasis model of assessment - insulin resistance (HOMA-IR) at 4 weeks
HOMA-IR will be calculated based on fasting glucose and fasting insulin levels through the Mathews equation. Fasting glucose and insulin will be measured in serum via a photometric method in a biochemical analyzer.
Change from baseline in total cholesterol at 4 weeks
Total cholesterol will be measured in serum via a photometric method in a biochemical analyzer.
Change from baseline in low-density lipoprotein (LDL) cholesterol at 4 weeks
LDL cholesterol will be measured in serum via a photometric method in a biochemical analyzer.
Change from baseline in high-density lipoprotein (LDL) cholesterol at 4 weeks
HDL cholesterol will be measured in serum via a photometric method in a biochemical analyzer.
Change from baseline in triglycerides at 4 weeks
Triglycerides will be measured in serum via a photometric method in a biochemical analyzer.
Change from baseline in uric acid at 4 weeks
Uric acid will be measured in serum via a photometric method in a biochemical analyzer.
Change from baseline in urea at 4 weeks
Urea will be measured in serum via a photometric method in a biochemical analyzer.
Change from baseline in high sensitivity C-reactive protein (hsCRP) at 4 weeks
hsCRP will be measured in serum via an enzyme-linked immunoassay.
Change from baseline in systolic blood pressure (SBP) at 4 weeks
SBP will be measured with an automatic device operating on the oscillometric principle.
Change from baseline in diastolic blood pressure (DBP) at 4 weeks
DBP will be measured with an automatic device operating on the oscillometric principle.
Secondary Outcome Measures
Change from baseline in hematocrit at 4 weeks
Hematocrit will be measured in a hematology analyzer.
Change from baseline in iron at 4 weeks
Iron will be measured in serum via a photometric method in a biochemical analyzer.
Change from baseline in ferritin at 4 weeks
Ferritin will be measured in serum via a chemiluminescent immunoassay in a biochemical analyzer.
Change from baseline in total iron binding capacity at 4 weeks
Total iron binding capacity will be measured in serum via a photometric method in a biochemical analyzer.
Change from baseline in albumin at 4 weeks
Albumin will be measured in serum via a photometric method in a biochemical analyzer.
Change from baseline in alanine aminotransferase (ALT) at 4 weeks
ALT will be measured in serum via a photometric method in a biochemical analyzer.
Change from baseline in gamma-glutamyl transferase (GGT) at 4 weeks
GGT will be measured in serum via a photometric method in a biochemical analyzer.
Full Information
NCT ID
NCT05582720
First Posted
October 13, 2022
Last Updated
March 6, 2023
Sponsor
Harokopio University
Collaborators
Hellenic Catering S.A., Laboratory of Design and Process Analysis, School of Chemical Engineering, National Technical University of Athens, Laboratory of Biotechnology, Department of Biological Applications & Technology, University of Ioannina, European Regional Development Fund, Operational Program "Competitiveness, Entrepreneurship and Innovation", Project Code: T2EDK- 02830)
1. Study Identification
Unique Protocol Identification Number
NCT05582720
Brief Title
Cardioprotective Properties of Vegan Burger
Acronym
VeganBurger
Official Title
Development of Innovative Functional Meat Analogues Using Alternative Sources of Plant Proteins and Novel Technologies
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 1, 2022 (Actual)
Primary Completion Date
May 2023 (Anticipated)
Study Completion Date
May 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Harokopio University
Collaborators
Hellenic Catering S.A., Laboratory of Design and Process Analysis, School of Chemical Engineering, National Technical University of Athens, Laboratory of Biotechnology, Department of Biological Applications & Technology, University of Ioannina, European Regional Development Fund, Operational Program "Competitiveness, Entrepreneurship and Innovation", Project Code: T2EDK- 02830)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Several studies over the last decades have demonstrated the important role of nutrition in the development of chronic diseases, such as cardiovascular disease and cancer. One dietary component that has been in the center of scientific research is red meat and processed meat (e.g., cold cuts, sausages, burgers). Burger, in particular, is one of the most popular red meat products and its consumption has increased rapidly in recent years due to the expansion of fast-food restaurants, its wide availability and its low price. However, due to its high animal fat content which is mostly saturated and high degree of processing, its nutritional value and the safety of its long-term high consumption have been questioned. The wide acceptance of burger by the general population, combined with the perception that it is a "burdensome" food for health, makes it an ideal subject for interventions aiming at modifying its nutritional value without downgrading its organoleptic characteristics and increasing its cost. Such an approach could be applied to the meat industry in order to develop innovative, functional meat analogues of high nutritional and organoleptic value, which could find acceptance by both meat-eating and vegetarian/vegan populations. Therefore, the aim of the present double-blind, randomized, crossover clinical trial is to explore the potential cardioprotective properties of "vegan burger", a novel meat analogue developed through the substitution of animal proteins and lipids with plant-based constituents using innovative technologies, against the conventional animal-based burger, in apparently healthy volunteers.
Detailed Description
The nutritional value and health effects of red meat and processed meat products (e.g., cold cuts, sausages, burgers) remain the object of intense research and scientific controversy in the fields of Nutrition and Food Science. Red meat is a rich source of macronutrients (e.g., proteins of high biological value) and several micronutrients (e.g., iron), and a food group particularly appealing to consumers. However, in recent years there has been an increase in the total consumption of red meat and processed meat products in developed countries, which has been associated with both increased risk of chronic diseases (e.g., cardiovascular diseases, obesity, diabetes mellitus, various types of cancer and autoimmune diseases) and increased total mortality. The aggravating effect of red meat consumption on health is likely attributed to its increased content of saturated fatty acids, which have been associated with the occurrence of insulin resistance, dyslipidemia, and disturbances in the intestinal microbiota, as well as other components produced during its processing (e.g., oxidized forms of fat, heterocyclic amines, polycyclic aromatic hydrocarbons), which can trigger mechanisms of inflammation, oxidative stress and carcinogenesis, and further contribute to the pathogenesis of cardiometabolic and neoplastic diseases. Based on the available research data, scientific associations and health organizations at the local and international level recommend limiting the consumption of red meat and meat products and replacing them with products of plant origin in the context of adopting a balanced health-promoting diet and reducing the risk of chronic cardiometabolic disorders in the general population.
Burger is one of the most popular meat products and its consumption has increased rapidly in recent years due to the expansion of fast-food restaurants, its wide availability and its low price. However, due to its high content in animal fat, which is mostly saturated, its nutritional value and the safety of its long-term high consumption have been questioned. The wide acceptance of burger by the general population, combined with the perception that it is a "burdensome" food for health, makes it an ideal subject for interventions aiming at modifying its nutritional value without simultaneously degrading its organoleptic characteristics and increasing its cost. Such an approach could be applied to the meat industry in order to develop innovative, functional meat analogues of high nutritional value, which could also find acceptance by meat-eating populations. The challenges in this direction are many, such as the reduction of lipids and/or the replacement of saturated fatty acids with other health-beneficial lipids without degrading the texture and taste of the product, and the replacement of animal proteins with plant proteins. Until now, the majority of commercially available meat analogs are made from soy protein or gluten. However, protein products have also been developed from other raw materials, including vegetables and legumes (e.g., peas and chickpeas). In addition, protein products from fungi and bacteria are available, which are suitable for reproducing the taste and texture of meat. Regarding fat, various ingredients have also been explored as substitutes for animal fat, such as dietary fiber and vegetable oils.
The aim of the present study is to explore the potential cardio-protective effects of an innovative burger of high nutritional and organoleptic value (vegan burger), developed through the substitution of animal proteins and lipids with plant-based constituents using innovative technologies, compared to a conventional burger, in apparently healthy subjects.
The study will be a randomized, cross-over, double blind clinical trial. The study sample will consist of 15 apparently healthy subjects aged 30-60 years, with a body mass index of ≥25 kg/m2 and a habitual red meat consumption of ≥3 times/week. Candidates will be excluded from the study on the basis of the following: i) presence of chronic diseases, such as diabetes mellitus, active cancer, cardiovascular, liver kidney, respiratory, gastrointestinal, chronic inflammatory and psychiatric diseases; ii) use of certain types of medication, i.e., immunosuppressants, anti-inflammatory drugs and cortisol, and dietary supplements, i.e., protein, amino acids, fatty acids, dietary fiber, probiotics and prebiotics (other prescribed medications and micronutrient supplements will be allowed, provided that their reception will remain stable throughout the trial); iii) habitual excessive consumption of alcohol (>210 g and >140 g of ethanol per week for men and women, respectively), iv) currently being on a restrictive diet (e.g., weight loss or vegetarian diet) or any significant recent change (within 6 months) in lifestyle habits, and v) pregnancy and breastfeeding for women.
Participants will be randomized to consume 2 servings per week of either a conventional burger or a vegan burger (serving size: 150 g of raw product corresponding to 120 g of cooked product) for 4 weeks, with a 2-week wash-out period between the two interventions. Randomization will be performed by a researcher with no clinical involvement in the study and will be blind to all members of the research team.
All burger products will be prepared by a certified food industry (Hellenic Catering S.A.) based on current food safety legislation and quality assurance specifications. The conventional burger will be the animal(beef)-based burger already produced and marketed by the company, while the experimental burger (vegan burger) will be developed using innovative technologies from plant-based products, such as proteins and dietary fibers from legumes and edible strains of basidiomycetes, lipids of plant origin rich in n-3 polyunsaturated fatty acids and other bioactive components. The development of the methodologies for the isolation of the raw materials will be performed by the Laboratory of Design and Process Analysis, School of Chemical Engineering, National Technical University of Athens and the Laboratory of Biotechnology, Department of Biological Applications & Technology, University of Ioannina. The development of the experimental vegan burger to be used in the dietary intervention will take place in a pilot unit of Hellenic Catering S.A. A product preparation will be designed with the incorporation of vegetable proteins from meat analogues, with the aim of the final product composition meeting the desired technical characteristics of structure and texture as well as the organoleptic characteristics of a burger. An appropriate mold and molding machine will be selected to shape the product, and appropriate packaging, preservation and processing methods (e.g., sock freezing, chilling, cooking) will be utilized. The two burger products will have a common shape and organoleptic characteristics (odor, texture and taste).
Participants will be given additional instructions to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort throughout the study. The study physician will be on a weekly contact with each participant to systematically record potential side-effects and will be in charge of terminating the intervention if needed. Participants' adherence to the intervention will be assessed through weekly self-monitoring diaries, in which subjects will record the day of consumption, the quantity and the cooking method of the burger products, along with other dietary characteristics and the use of medications and dietary supplements. Participants will be evaluated at the start and at the end of each intervention period (total of 4 evaluations) in terms of anthropometric indices, body composition, and lifestyle habits (diet and physical activity) through validated questionnaires, while fasting blood and first-morning urine samples will be taken to determine laboratory parameters (glucose metabolism indices, lipidemic profile, liver enzymes, inflammatory and oxidative stress markers, etc.). All biological samples will be collected and analyzed in the Laboratory of Clinical Nutrition and the Laboratory of Biology, Biochemistry, Physiology and Microbiology, Department of Nutrition and Dietetics, Harokopio University of Athens, by experienced personnel.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiometabolic Health
Keywords
read meat, meat analogues, burger, vegan burger, dietary intervention, plant proteins, inflammation, oxidative stress, thrombosis, cardioprotection
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Care ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
15 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Conventional burger group
Arm Type
Active Comparator
Arm Description
This arm will consume 2 portions (each 120 g cooked) of conventional burger per week for a 4-week period.
Arm Title
Vegan burger group
Arm Type
Experimental
Arm Description
This arm will consume 2 portions (each 120 g cooked) of vegan burger per week for a 4-week period.
Intervention Type
Behavioral
Intervention Name(s)
Conventional burger
Intervention Description
Participants initially randomized to this intervention arm will be provided with a total of 8 conventional burgers and will be asked to consume them twice weekly for 4 weeks. Conventional burgers will be produced by Hellenic Catering S.A. using standard procedures. Participants will also be instructed to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort during the intervention. After a 2-week wash-out period (no burger consumption), participants will cross over to the other intervention arm.
Intervention Type
Behavioral
Intervention Name(s)
Vegan burger
Intervention Description
Participants initially randomized to this intervention arm will be provided with a total of 8 vegan burgers and will be asked to consume them twice weekly for 4 weeks. Vegan burgers will be produced by Hellenic Catering S.A. using novel technologies. Participants will also be instructed to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort during the intervention. After a 2-week wash-out period (no burger consumption), participants will cross over to the other intervention arm.
Primary Outcome Measure Information:
Title
Change from baseline in homeostasis model of assessment - insulin resistance (HOMA-IR) at 4 weeks
Description
HOMA-IR will be calculated based on fasting glucose and fasting insulin levels through the Mathews equation. Fasting glucose and insulin will be measured in serum via a photometric method in a biochemical analyzer.
Time Frame
0 (baseline) and 4 weeks
Title
Change from baseline in total cholesterol at 4 weeks
Description
Total cholesterol will be measured in serum via a photometric method in a biochemical analyzer.
Time Frame
0 (baseline) and 4 weeks
Title
Change from baseline in low-density lipoprotein (LDL) cholesterol at 4 weeks
Description
LDL cholesterol will be measured in serum via a photometric method in a biochemical analyzer.
Time Frame
0 (baseline) and 4 weeks
Title
Change from baseline in high-density lipoprotein (LDL) cholesterol at 4 weeks
Description
HDL cholesterol will be measured in serum via a photometric method in a biochemical analyzer.
Time Frame
0 (baseline) and 4 weeks
Title
Change from baseline in triglycerides at 4 weeks
Description
Triglycerides will be measured in serum via a photometric method in a biochemical analyzer.
Time Frame
0 (baseline) and 4 weeks
Title
Change from baseline in uric acid at 4 weeks
Description
Uric acid will be measured in serum via a photometric method in a biochemical analyzer.
Time Frame
0 (baseline) and 4 weeks
Title
Change from baseline in urea at 4 weeks
Description
Urea will be measured in serum via a photometric method in a biochemical analyzer.
Time Frame
0 (baseline) and 4 weeks
Title
Change from baseline in high sensitivity C-reactive protein (hsCRP) at 4 weeks
Description
hsCRP will be measured in serum via an enzyme-linked immunoassay.
Time Frame
0 (baseline) and 4 weeks
Title
Change from baseline in systolic blood pressure (SBP) at 4 weeks
Description
SBP will be measured with an automatic device operating on the oscillometric principle.
Time Frame
0 (baseline) and 4 weeks
Title
Change from baseline in diastolic blood pressure (DBP) at 4 weeks
Description
DBP will be measured with an automatic device operating on the oscillometric principle.
Time Frame
0 (baseline) and 4 weeks
Secondary Outcome Measure Information:
Title
Change from baseline in hematocrit at 4 weeks
Description
Hematocrit will be measured in a hematology analyzer.
Time Frame
0 (baseline) and 4 weeks
Title
Change from baseline in iron at 4 weeks
Description
Iron will be measured in serum via a photometric method in a biochemical analyzer.
Time Frame
0 (baseline) and 4 weeks
Title
Change from baseline in ferritin at 4 weeks
Description
Ferritin will be measured in serum via a chemiluminescent immunoassay in a biochemical analyzer.
Time Frame
0 (baseline) and 4 weeks
Title
Change from baseline in total iron binding capacity at 4 weeks
Description
Total iron binding capacity will be measured in serum via a photometric method in a biochemical analyzer.
Time Frame
0 (baseline) and 4 weeks
Title
Change from baseline in albumin at 4 weeks
Description
Albumin will be measured in serum via a photometric method in a biochemical analyzer.
Time Frame
0 (baseline) and 4 weeks
Title
Change from baseline in alanine aminotransferase (ALT) at 4 weeks
Description
ALT will be measured in serum via a photometric method in a biochemical analyzer.
Time Frame
0 (baseline) and 4 weeks
Title
Change from baseline in gamma-glutamyl transferase (GGT) at 4 weeks
Description
GGT will be measured in serum via a photometric method in a biochemical analyzer.
Time Frame
0 (baseline) and 4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age 30-60 years old
Body mass index ≥25 kg/m2
Habitual red meat consumption ≥3 portions/week (1 portion: 120 g cooked meat)
Exclusion Criteria:
Presence of chronic diseases, such as diabetes mellitus, active cancer, cardiovascular, liver kidney, respiratory, gastrointestinal, chronic inflammatory and psychiatric diseases
Reception of immunosuppressant, anti-inflammatory or cortisol medication,
Intake of protein, amino acid, fatty acid, dietary fiber, probiotic and prebiotic supplements
Habitual excessive alcohol consumption, i.e., >210 g and >140 g of ethanol per week for men and women, respectively
Currently being on a restrictive diet (e.g., weight loss or vegetarian diet) or any significant recent change (within 6 months) in lifestyle habits
Pregnancy and breastfeeding for women
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tzortzis Nomikos, PhD
Phone
+302109549100
Ext
305
Email
tnomikos@hua.gr
First Name & Middle Initial & Last Name or Official Title & Degree
Michael Georgoulis, PhD
Phone
+302109549100
Ext
329
Email
mgeor@hua.gr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tzortzis Nomikos, PhD
Organizational Affiliation
Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Smaragdi Antonopoulou, PhD
Organizational Affiliation
Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Elizabeth Fragopoulou, PhD
Organizational Affiliation
Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Meropi Kontogianni, PhD
Organizational Affiliation
Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Michael Georgoulis, PhD
Organizational Affiliation
Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University
Official's Role
Study Director
Facility Information:
Facility Name
Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University
City
Kallithea
State/Province
Attica
ZIP/Postal Code
17676
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tzortzis Nomikos, PhD
Phone
+302109549100
Ext
305
Email
tnomikos@hua.gr
First Name & Middle Initial & Last Name & Degree
Michael Georgoulis, PhD
Phone
+302109549100
Ext
329
Email
mgeor@hua.gr
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Deidentified participant data will be shared to investigators for the purpose of data meta-analysis, provided that the proposed use has been approved by the Study Principal Investigator. Proposals should be directed to tnomikos@hua.gr. To gain access, data requestors will need to sign a data access agreement.
Learn more about this trial
Cardioprotective Properties of Vegan Burger
We'll reach out to this number within 24 hrs